Genzyme Molecular Oncology Q3 Losses Decrease, Beat Estimates | GenomeWeb

NEW YORK, Oct. 19 - Genzyme Molecular Oncology, which recently licensed its Serial Analysis of Genomic Expression database to Celera, shrank its losses by 38 percent this quarter, beating Wall Street's expecations by 8 cents per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.